The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
This article discussed the Federal investigation into payments made by orthopedic implant manufacturers and physicians who use these products. While there are certainly appropriate consulting arrangements, these can be easily abused and there will be more investigations, not just in ortho...
While pharmaceutical companies raised prices at a higher level than general inflation, implementing price controls is not the appropriate means to control drug spend. More effort needs to be placed on clinical trials and the demonstration of efficacy and value prior to a products release. ...
Naturally Police Departments are concerned about the weight of their officers, given the physical nature of the work for those on the beat, but this issue is beginning to be raised in the general employer arena. For employers to be successful with this type of approach, they need to go beyond...
Ongoing healthcare inflation at 200-400%/yr of CPI has surpassed the point where employers can easily compete with international products and services. We are already seeing growth in Scheduled Medical Benefits, which are a poor substitute - but do substitute for...
1) Baxter was producing 50% of the worlds heparin requirements, which provided short term anticoagulation for hemodialysis and various interventions for cardiovascular disease. 2) The base product of heparin comes from porcine intestines. 3) The base product of Baxter's heparin was...
1) Amgen's and J&J's ESA products are going to continue to receive more black box warnings from the FDA. 2) A federal Judge may force Amgen to accept a royalty from Roche, allowing their CERA ESA to come to market in the USA. 3) Their is potential for more problems to arise,...
The Wall Street Journal published another article speculating on the possibilities of a private equity buyout of McKesson (MCK). I still view McKesson as the most logical LBO target among the Big 3 wholesalers, especially given its business mix, current operating platform, age (and stability)...
The recent uptick in the DEA’s enforcement activities with wholesalers is likely to continue as the DEA seeks to combat diversion of legitimate controlled substances. As I see it, the increase stems from a combination of changing political priorities, new detection capabilities, and new approaches to...
Health Plans are going to have to radically change their systems and approaches if they expect to improve their success in the long run. The system as currently structured dis-incents Health Plans from doing the right thing, actually managing health. This requires a long term commitment...
The DEA’s aggressive enforcement efforts for the diversion of controlled substances and other prescription drugs may mean business disruptions for wholesalers besides Cardinal Health (CAH), including AmerisourceBergen (ABC). For better (or perhaps worse), the DEA now considers distributors and...